Vaxart

Vaxart is a South San Francisco oral vaccine biotech founded in 2007. The proprietary VAAST oral tablet platform delivers room-temperature-stable recombinant protein vaccines that activate mucosal immunity directly in the gut — the opposite of traditional intramuscular jabs. The pipeline: norovirus Phase 2 bivalent oral tablet (the largest unmet vaccine market with no FDA-approved competitor), COVID-19 Phase 2b oral tablet under the BARDA Project NextGen 460 million USD contract awarded June 2024, and seasonal influenza H1N1 oral tablet Phase 2.

The defining 2024-2025 event is the BARDA Project NextGen contract. The 460 million USD BARDA-HHS award positions Vaxart’s oral COVID tablet for a 10000-participant Phase 2b efficacy and immunogenicity trial. The cash carries the company through to 2026 without dilution. Importantly, after the Trump-RFK Jr HHS transition in 2025, the Vaxart Phase 2b portion of Project NextGen was specifically continued (other Project NextGen awards were frozen), reflecting bipartisan recognition that needle-free room-temperature vaccines reduce strategic biodefense risk.

Financials reflect contract-revenue recognition not biotech-distress: trailing revenue 255.6 million USD with growth 87.9 percent year over year (BARDA milestone receipts), gross margin 21.14 percent (contract-recognition pass-through, not normal biotech), operating margin 13.19 percent positive, profit margin 14.51 percent positive, EPS 0.16 USD trailing positive. Forward P/E minus 1.01 reflects expected post-BARDA-recognition loss return. Free cash flow minus 31.7 million USD (operating burn continues despite revenue). EV/Revenue 0.45, EV/EBITDA 2.54 — distressed multiples on a temporarily-profitable biotech. Market cap 164.5 million USD micro-cap. 9.4 percent short interest. The stock trades at 72.4 percent of its 52-week range (0.26 to 0.84 USD).

The investor base is the unusual feature. Vaxart was the original 2020 BARDA Operation Warp Speed pandemic-trade speculation that crashed when it failed to secure Phase 3 funding for Vaxart-1 COVID tablet. Many retail holders never sold; institutional ownership is dominated by Renaissance Technologies systematic, Citadel market-making, and Armistice Capital tactical biotech positions. Insider ownership is low. The 9.4 percent short interest with 2.61 days to cover reflects continued biotech-skeptic positioning. Two analysts (B. Riley, HC Wainwright) hold buy with mean target 3.00 USD — implied 341.18 percent upside, the highest in our coverage. The setup is option-like: zero conviction in 13F flow, but valuation embedded reflects no value for the Phase 2b efficacy readout.

EV/Revenue 0.45 prices Vaxart as if BARDA revenue is zero — peer biotech that has received BARDA awards trades at 5-15x EV/Revenue on recognized contracts. Even if the contract revenue normalizes to a 30-50 million USD steady-state, EV/Revenue should be 3-5x, implying 100-300 million USD EV — already higher than current 73 million USD EV. On a sum-of-parts basis, BARDA contract alone is worth 200-300 million USD net present value if it runs to Phase 3, plus the norovirus pipeline at 50-150 million USD risk-adjusted, plus the seasonal flu platform option. Conservative SOTP is 350-500 million USD market cap, or 1.45 to 2.06 USD per share — 115 to 200 percent upside. Analyst mean 3.00 USD assumes successful Phase 2b and norovirus advancement.

1. :
2. :
3. :

Vaxart is a binary clinical-stage biotech with rare government-funded de-risking. The BARDA Project NextGen contract is the unusual feature — 460 million USD non-dilutive funding for a 164 million USD market cap company, with the contract surviving the 2025 HHS transition. The investable thesis is the Vaxart-2 Phase 2b efficacy readout in 2026: positive data triggers strategic interest from large pharma; negative data resets to norovirus-pipeline-only valuation. The 341 percent upside to consensus is real but the path is non-linear. Position size 0.5 to 1 percent of portfolio, accept that this is option-style risk-reward. Watch for BARDA contract milestone disclosures, norovirus Phase 2 readouts and any strategic-partnership announcement.